Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled date : 2021 - 10 - 25 save search
DICE Therapeutics Initiates Phase 1 Clinical Trial of S011806 for the Treatment of Psoriasis
Published: 2021-10-25 (Crawled : 13:00) - biospace.com/
DICE | $47.55 0.06% 0.08% 0
|
|
| O: 2.14%
H: 0.0%
C: -1.13%
psoriasis treatment phase 1 trial phase 2 phase 3
Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109
Published: 2021-10-25 (Crawled : 13:00) - biospace.com/
AQST | $4.11 -8.67% -9.49% 2.3M
|
Health Technology
|
| O: 1.64%
H: 9.45%
C: 7.6%
phase 1 positive topline trial phase 2 phase 3
Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection
Published: 2021-10-25 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.1%
H: 0.86%
C: 0.78%
treatment positive results trials phase 3 trial hiv topline injection infections
Concert Pharmaceuticals Completes Enrollment in THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
Published: 2021-10-25 (Crawled : 12:00) - biospace.com/
CNCE | $8.37 0.36% 0
|
Health Technology
|
| O: -2.17%
H: 1.85%
C: -0.37%
phase 3 trial enroll
FibroGen Announces Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2021
Published: 2021-10-25 (Crawled : 11:00) - globenewswire.com
FGEN | $1.15 -1.71% -1.74% 1.3M
|
Health Technology
|
| O: 0.0%
H: 3.41%
C: 3.13%
phase 3 kidney
Second Dupixent® (dupilumab) Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Disease Improvements, Underscoring Role of Type 2 Inflammation in This Complex Disease
Published: 2021-10-25 (Crawled : 05:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.02%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.89%
H: 0.26%
C: -0.12%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.38%
H: 0.88%
C: 0.44%
disease phase 3 trial dupixent
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.